Ventures
We model ventures with realistic growth and market size assumptions and only invest when the opportunity presents a risk adjusted NPV that appropriately compensates our firms opportunity cost of capital.
We model ventures with realistic growth and market size assumptions and only invest when the opportunity presents a risk adjusted NPV that appropriately compensates our firms opportunity cost of capital.
Some Former Companies In The Portfolio
Myokardia (MYOK) acquired by Bristol Myers Squibb in 2020 for $13.1 billion
Pandion Therapeutics(PAND) acquired by Merck in 2021 for $1.85 billion